NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Final Summary of NWBO differences vs IMUC:

1.KEY is ALL Antigens for NWBO vs just 6 Antigens for IMUC
2. NWBO's DCVAX L is close to completion in Ph 3 vs IMUC in early phase 3 of beginning to enroll.
3. NWBO DC VAX L Trial results by 2017? and IA in next month or so whereas for
IMUC (July 2016 verfied):
Estimated Study Completion Date: December 2021
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
4. NWBO response to curing NASD delisting due to <$1:

The Company intends to monitor the closing bid price of its common stock on an ongoing basis, and consider a range of available options to regain compliance with the share price listing standard. The Company could remedy the deficiency, either now or at a later date, through a reverse stock split. However, the Company currently plans to regain compliance by focusing on progress in its operational programs.

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11469954&RcvdDate=6/30/2016&CoName=NORTHWEST%20BIOTHERAPEUTICS%20INC&FormType=8-K&View=html

Sept 1 SEC 8K filing: IMUC response to delisting due to <$1:

The Company is currently reviewing the deficiency identified in the Notice and has begun the process of preparing a plan of compliance. The Company (IMUC) is considering the option of seeking approval of an amendment to the Company’s certificate of incorporation, which would authorize a reverse stock split, at a Special Meeting of Stockholders.
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11576455&RcvdDate=9/1/2016&CoName=IMMUNOCELLULAR%20THERAPEUTICS%2C%20LTD.&FormType=8-K&View=html

From 8K filed 8/22/16: BIG DILUTION@16 cents was reason for LARGE VOLUME + UNDER WATER:

Subsequent to June 30, 2016, ImmunoCellular entered into an underwriting agreement with Maxim Group LLC, pursuant to which it sold 34,550,000 shares of common stock, pre-funded warrants to purchase 12,450,000 shares of ImmunoCellular’s common stock and base warrants to purchase 35,250,000 shares of its common stock. The common stock and base warrants were sold at a combined public offering price of $0.16, and the base warrants were approved for listing on the NYSE MKT under the symbol “IMUC.WS.” The pre-funded warrants were sold to certain investors in lieu of common stock less the $0.01 per share exercise price for each pre-funded
warrant. The base warrants have an exercise price of $0.1921 per share. Additionally, ImmunoCellular granted the underwriters a 45 day option to purchase up to an additional 7,050,000 shares of common stock and/or base warrants to purchase 5,287,000 shares of its common stock. On August 12, 2016, the underwriters exercised the option to purchase 4,478,625 of additional base warrants at a price of $0.01266 per base warrant. The gross proceeds from the offering are approximately $7.5 million.

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11558588&RcvdDate=8/22/2016&CoName=IMMUNOCELLULAR%20THERAPEUTICS%2C%20LTD.&FormType=8-K&View=html

5) Why didn't NWBO do LARGER OFFERING in the last two pipsqueak offerings of less than $3 mln vs over $7 mln for IMUC>

6)AND ALL posters on 8/31 on IMUC: Lost it as interest in trading it (GOT FLEECED) & IRRELEVANT ! The MASSIVE IMUC trading due to what I indicated PREVIOUSLY which NOBODY thought of: FINANCING DEAL was SEC Effective and done 8/31!:

AND that was the real reason why IMUC fell off the cliff from ~20 cents to ~11 cents! due to sheer size of offering!